Rhythm Pharmaceuticals: On the Path to a Pioneer Role in Rare Obesity

Stock fireworks after study data: Rhythm impresses with strong phase-2 results for an oral obesity therapy and catapults itself into the focus of institutional investors. Market creates the company itself: Over 80,000 genetically tested individuals form the basis for a scalable patient strategy. The stock of Rhythm Pharmaceuticals made headlines on July 9, 2025: After the release of clinical study data, the stock shot up by more than 36% to a new all-time high. But who is behind this little-known biotech company that suddenly comes into...